Tricida, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Operating income | −$153.0M | −$251.4M | −$178.8M | −$103.6M | −$47.1M |
| Net income | −$176.6M | −$264.8M | −$37.9M | −$102.8M | −$41.3M |
| Total assets | $168.5M | $351.7M | $371.8M | $247.8M | $70.6M |
| Total liabilities | $168.3M | $242.8M | $107.9M | $53.3M | $11.5M |
| Equity | $218,000 | $108.9M | $263.9M | $194.5M | −$88.0M |
| EPS (diluted) | $-3.44 | $-5.29 | — | — | — |
| Shares out. | 50.2M | 49.9M | 42.4M | 42.1M | 2.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2021- Operating margin
- —
- Net margin
- —
- Return on equity
- −80993.6%
- Return on assets
- −104.8%
- Return on capital (ROCE)
- −110.0%
- Liabilities / assets
- 99.9%
- Debt / equity
- 771.96×
- Book value / share
- $0.00
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2021- Altman Z″ (distress)
- -17.26distress
- Accruals / assets
- −21.7%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 2 warning● 1 good- Altman Z″ in the distress zone
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Bankruptcy or receivership · Modified shareholder rights · Other material eventJun 13, 2023
- Bankruptcy or receivership · Regulation FD disclosureMay 25, 2023
- Regulation FD disclosureApr 26, 2023
- Regulation FD disclosureMar 24, 2023
- Director / officer changeMar 21, 2023
- Completed an acquisition or dispositionMar 15, 2023
- Entered a material agreementFeb 24, 2023
- Regulation FD disclosureFeb 23, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.